This research trial studies quality of life after bladder-preservation chemotherapy and radiation therapy (chemo-radiotherapy) in patients with bladder cancer that has spread into or through the muscle layer of the bladder (muscle-invasive bladder cancer). Bladder-preservation chemo-radiotherapy is a standard treatment for patients with muscle-invasive bladder cancer, however, chemo-radiotherapy may cause urinary tract, bowel, and sexual late side effects that negatively affect patients' quality of life. Studying quality-of-life in patients with muscle-invasive bladder cancer after chemo-radiotherapy may help identify the long-term side effects of treatment and may help plan the best treatment in the future and improve patients' quality of life.

Brief Title

Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer

Official Title

Prospective Study of Bladder-Preservation Chemo-Radiotherapy (Partial Bladder Hypo-fractionated Radiotherapy) for Patients With Muscle-Invasive Bladder Cancer

Brief Summary

This research trial studies quality of life after bladder-preservation chemotherapy and<br /> radiation therapy (chemo-radiotherapy) in patients with bladder cancer that has spread into<br /> or through the muscle layer of the bladder (muscle-invasive bladder cancer).<br /> Bladder-preservation chemo-radiotherapy is a standard treatment for patients with<br /> muscle-invasive bladder cancer, however, chemo-radiotherapy may cause urinary tract, bowel,<br /> and sexual late side effects that negatively affect patients' quality of life. Studying<br /> quality-of-life in patients with muscle-invasive bladder cancer after chemo-radiotherapy may<br /> help identify the long-term side effects of treatment and may help plan the best treatment in<br /> the future and improve patients' quality of life.

Detailed Description

PRIMARY OBJECTIVES:

I. To study health-related quality of life (HRQoL, or QOL) for patients undergoing
protocol-based bladder-preservation chemo-radiation.

OUTLINE:

Patients complete the European Organization for Research and Treatment for Cancer (EORTC)
QLQ-Bladder Cancer Muscle Invasive (BLM-C30) at baseline, every 3 months for 1 year, every 4
months for 1 year, every 6 months for 3 years, and then annually thereafter after completion
of chemo-radiotherapy.

Outcome Measures

Outcome measures are the tests that investigators perform to prove whether or not a treatment being tested in a clinical trial is having any effect.